Stay updated on ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial page.

Latest updates to the ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has removed detailed information about a phase 2 study of abraxane with pembrolizumab for advanced urothelial carcinoma, including inclusion and exclusion criteria, while adding a reference to Urothelial Carcinoma and a new revision number.SummaryDifference34%
- Check30 days agoChange DetectedThe page has updated its version from v2.14.2 to v2.14.4, indicating a revision in the content. Additionally, the previous estimated timestamps for 'Results First Posted' and 'Last Update Posted' have been removed.SummaryDifference0.2%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check94 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABLE: Abraxane + Anti-PD1/PDL1 in Adv Urothelial Cancer Clinical Trial page.